Clinical and laboratory characteristics of patients with CML at diagnosis and at asciminib initiation (n = 34)
| Variables . | n (%) . |
|---|---|
| Age at diagnosis, median (range), y | 44.5 (6-74) |
| Age at asciminib initiation, median (range), y | 51.5 (14-78) |
| Sex, male | 22 (64.7) |
| CML phase at diagnosis | |
| Chronic | 31 (91.2) |
| Accelerated | 3 (8.8) |
| CML phase at asciminib initiation | |
| Chronic | 26 (83) |
| Accelerated | 4 (12.5) |
| BC | 2 (6) |
| Sokal score (diagnosis) | |
| Low | 7 (20.6) |
| Intermediate | 8 (23.5) |
| High | 9 (26.5) |
| Missing | 10 (29.4) |
| ELTS score (diagnosis) | |
| Low | 11 (32.4) |
| Intermediate | 14 (43) |
| High | 5 (14.7) |
| Missing | 7 (20.6) |
| BCR::ABL1 mutations | |
| No mutations | 20 (58.8) |
| T315I | 7 (20.5) |
| Other mutations∗ | 6 (18) |
| Not analyzed | 1 (2.9) |
| ACAs at asciminib initiation | |
| No ACAs | 16 (47) |
| Not available | 17 (50) |
| Missing | 1 (3) |
| Baseline BCR::ABL1 transcripts % IS (before asciminib), median (range) | 25 (0.1-184) |
| Previous therapeutics lines | |
| 2-3 | 29 (85.3) |
| ≥4† | 5 (14.7) |
| Variables . | n (%) . |
|---|---|
| Age at diagnosis, median (range), y | 44.5 (6-74) |
| Age at asciminib initiation, median (range), y | 51.5 (14-78) |
| Sex, male | 22 (64.7) |
| CML phase at diagnosis | |
| Chronic | 31 (91.2) |
| Accelerated | 3 (8.8) |
| CML phase at asciminib initiation | |
| Chronic | 26 (83) |
| Accelerated | 4 (12.5) |
| BC | 2 (6) |
| Sokal score (diagnosis) | |
| Low | 7 (20.6) |
| Intermediate | 8 (23.5) |
| High | 9 (26.5) |
| Missing | 10 (29.4) |
| ELTS score (diagnosis) | |
| Low | 11 (32.4) |
| Intermediate | 14 (43) |
| High | 5 (14.7) |
| Missing | 7 (20.6) |
| BCR::ABL1 mutations | |
| No mutations | 20 (58.8) |
| T315I | 7 (20.5) |
| Other mutations∗ | 6 (18) |
| Not analyzed | 1 (2.9) |
| ACAs at asciminib initiation | |
| No ACAs | 16 (47) |
| Not available | 17 (50) |
| Missing | 1 (3) |
| Baseline BCR::ABL1 transcripts % IS (before asciminib), median (range) | 25 (0.1-184) |
| Previous therapeutics lines | |
| 2-3 | 29 (85.3) |
| ≥4† | 5 (14.7) |